Mandate

Vinge advises Surgical Science Sweden AB (publ) in connection with the acquisition of Mimic Technologies Inc and with a directed share issue

January 26, 2021 M&A

Vinge has advised Surgical Science Sweden AB (publ) (“Surgical Science”) in connection with its acquisition of all shares in Mimic Technologies Inc for an initial consideration of SEK 150 million with a maximum deferred contingent consideration of SEK 130 million.

In order to finance the acquisition, Surgical Science has carried out a directed share issue. The directed share issue comprised of 3,279,676 newly issued shares at a subscription price of SEK 98.30 per share, whereby Surgical Science will receive gross proceeds of approximately SEK 322 million before transaction related costs. The subscription price has been determined through an accelerated book‑building procedure and corresponds to a premium of approximately 1 per cent to the closing price of SEK 97.40 per share on 20 January 2021 on Nasdaq First North Growth Market.

Surgical Science is a world leader in the manufacture of virtual reality simulators for evidence-based laparoscopic and endoscopic training. The simulators enable surgeons and other medical specialists to train and improve their psychomotor skills and instrument handling before entering the operating room. In parallel with its own products, Surgical Science works with simulation solutions for medical technology companies that develop surgical instruments for clinical use, such as robotic surgery.

Vinge’s team has consisted of Fredrik Sonander (M&A) and Edin Agic (Capital Markets).

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025